Aktienanalyse zu Assembly Biosciences Inc (ASMB)ASMBAssembly Biosciences Inc

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Assembly Biosciences Inc is a good buy right now due to its current price of $20.09, which is significantly lower than analyst price targets of $52 and $53, indicating a potential upside of over 150%. Additionally, the company's gross margin remains strong at 100%, suggesting efficient operations despite recent losses. However, the main risk is the high forward P/E ratio of 500, indicating that the stock may be overvalued if future earnings do not meet expectations.